US 12,252,512 B2
Mutated polypeptides, compositions comprising the same, and uses thereof
Bruce C. Schnepp, Havertown, PA (US); and Philip R. Johnson, Bryn Mawr, PA (US)
Assigned to Interius Biotherapeutics, Inc., Philadelphia, PA (US)
Filed by INTERIUS BIOTHERAPEUTICS, INC., Philadelphia, PA (US)
Filed on Jul. 25, 2023, as Appl. No. 18/358,358.
Claims priority of provisional application 63/507,783, filed on Jun. 13, 2023.
Claims priority of provisional application 63/503,815, filed on May 23, 2023.
Claims priority of provisional application 63/391,939, filed on Jul. 25, 2022.
Claims priority of provisional application 63/391,930, filed on Jul. 25, 2022.
Prior Publication US 2024/0059744 A1, Feb. 22, 2024
Int. Cl. C12N 15/86 (2006.01); C07K 14/145 (2006.01)
CPC C07K 14/145 (2013.01) [C07K 2319/03 (2013.01); C07K 2319/30 (2013.01)] 33 Claims
 
1. A viral particle comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide having the formula T-S1, wherein T is a target binding domain and Sis a stalk portion,
wherein the heterologous viral glycoprotein is a VSV-G polypeptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 2;
wherein the target binding domain (T) comprises a scFv antibody that binds to CD7, wherein the scFv comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 30, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 32; and wherein the light chain variable region comprises a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 33, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 35; and
wherein the stalk portion S1 comprises a Fc protein comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 103, and wherein the S1 stalk portion is attached to the surface of the viral particle through a transmembrane domain.